Categories: EHRNewsPharmaceutical

Clene to Present at the 37TH Annual Roth Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1×1 investor meetings.

Date: March 18, 2025
Time of Presentation: 9:20 am PST
Format: Virtual Fireside Chat
1×1 Meetings: Please contact your Roth representative.

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Contacts:

Media Contact
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310
  Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

Staff

Recent Posts

Sightview Names Tycene Fritcher as CEO

Eyecare technology company will implement new branding, appoint key executives in organizational refreshDURHAM, N.C.--(BUSINESS WIRE)--#EHR--Sightview,…

43 minutes ago

Ash and Impilo Partner to Deliver Seamless At-Home Health Monitoring and Testing Nationwide

NEW YORK--(BUSINESS WIRE)--Ash, a leading at-home health testing platform, and Impilo, a leader in enabling…

44 minutes ago

IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement’

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial…

47 minutes ago

Barton Associates’ Dan Bassani Named to SIA’s 2025 “40 Under 40” List

Sales leader honored for driving AI transformation and accelerating growth across the organization PEABODY, Mass.,…

52 minutes ago

The Harbor Dental Society Partners with Torch Dental to Bring Efficiency and Cost Savings to Member Dentists

NEW YORK, June 16, 2025 /PRNewswire/ -- Torch Dental, a leading platform specializing in dental…

52 minutes ago

SAS unveils AI models and solutions for health care industry, payer organizations

New data and analytic products address complex health care issues of medication adherence, medical record…

52 minutes ago